nodes	percent_of_prediction	percent_of_DWPC	metapath
Naphazoline—Lacrimation—Pentoxifylline—systemic scleroderma	0.0618	0.0618	CcSEcCtD
Naphazoline—Ocular discomfort—Methotrexate—systemic scleroderma	0.0427	0.0427	CcSEcCtD
Naphazoline—Lacrimation increased—Pentoxifylline—systemic scleroderma	0.0395	0.0395	CcSEcCtD
Naphazoline—Keratitis—Mycophenolate mofetil—systemic scleroderma	0.0264	0.0264	CcSEcCtD
Naphazoline—Intraocular pressure increased—Prednisone—systemic scleroderma	0.0264	0.0264	CcSEcCtD
Naphazoline—Endophthalmitis—Prednisone—systemic scleroderma	0.0243	0.0243	CcSEcCtD
Naphazoline—Drowsiness—Pentoxifylline—systemic scleroderma	0.0203	0.0203	CcSEcCtD
Naphazoline—Sweating—Pentoxifylline—systemic scleroderma	0.0195	0.0195	CcSEcCtD
Naphazoline—Erythema—Pentoxifylline—systemic scleroderma	0.0159	0.0159	CcSEcCtD
Naphazoline—Tension—Pentoxifylline—systemic scleroderma	0.0156	0.0156	CcSEcCtD
Naphazoline—Nervousness—Pentoxifylline—systemic scleroderma	0.0154	0.0154	CcSEcCtD
Naphazoline—Vision blurred—Pentoxifylline—systemic scleroderma	0.015	0.015	CcSEcCtD
Naphazoline—Eye pain—Mycophenolate mofetil—systemic scleroderma	0.0137	0.0137	CcSEcCtD
Naphazoline—Hypertension—Pentoxifylline—systemic scleroderma	0.0137	0.0137	CcSEcCtD
Naphazoline—Discomfort—Pentoxifylline—systemic scleroderma	0.0134	0.0134	CcSEcCtD
Naphazoline—Hyperglycaemia—Leflunomide—systemic scleroderma	0.0129	0.0129	CcSEcCtD
Naphazoline—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.0125	0.0125	CcSEcCtD
Naphazoline—Hyperglycaemia—Mycophenolic acid—systemic scleroderma	0.0123	0.0123	CcSEcCtD
Naphazoline—Tension—Captopril—systemic scleroderma	0.0118	0.0118	CcSEcCtD
Naphazoline—Nervousness—Captopril—systemic scleroderma	0.0117	0.0117	CcSEcCtD
Naphazoline—Sweating—Mycophenolic acid—systemic scleroderma	0.0116	0.0116	CcSEcCtD
Naphazoline—Somnolence—Pentoxifylline—systemic scleroderma	0.0115	0.0115	CcSEcCtD
Naphazoline—Vision blurred—Captopril—systemic scleroderma	0.0114	0.0114	CcSEcCtD
Naphazoline—Hyperglycaemia—Lisinopril—systemic scleroderma	0.011	0.011	CcSEcCtD
Naphazoline—Eye disorder—Leflunomide—systemic scleroderma	0.0107	0.0107	CcSEcCtD
Naphazoline—Sweating—Lisinopril—systemic scleroderma	0.0105	0.0105	CcSEcCtD
Naphazoline—Eye disorder—Mycophenolic acid—systemic scleroderma	0.0102	0.0102	CcSEcCtD
Naphazoline—Discomfort—Captopril—systemic scleroderma	0.0101	0.0101	CcSEcCtD
Naphazoline—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00968	0.00968	CcSEcCtD
Naphazoline—Vision blurred—Leflunomide—systemic scleroderma	0.00936	0.00936	CcSEcCtD
Naphazoline—Asthenia—Pentoxifylline—systemic scleroderma	0.00931	0.00931	CcSEcCtD
Naphazoline—Tension—Mycophenolic acid—systemic scleroderma	0.00929	0.00929	CcSEcCtD
Naphazoline—Nervousness—Mycophenolic acid—systemic scleroderma	0.0092	0.0092	CcSEcCtD
Naphazoline—Sweating—Mycophenolate mofetil—systemic scleroderma	0.00917	0.00917	CcSEcCtD
Naphazoline—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00893	0.00893	CcSEcCtD
Naphazoline—Discomfort—Azathioprine—systemic scleroderma	0.00884	0.00884	CcSEcCtD
Naphazoline—Somnolence—Captopril—systemic scleroderma	0.00874	0.00874	CcSEcCtD
Naphazoline—Dizziness—Pentoxifylline—systemic scleroderma	0.00858	0.00858	CcSEcCtD
Naphazoline—Hypertension—Leflunomide—systemic scleroderma	0.00857	0.00857	CcSEcCtD
Naphazoline—Erythema—Lisinopril—systemic scleroderma	0.00853	0.00853	CcSEcCtD
Naphazoline—Tension—Lisinopril—systemic scleroderma	0.00837	0.00837	CcSEcCtD
Naphazoline—Discomfort—Leflunomide—systemic scleroderma	0.00835	0.00835	CcSEcCtD
Naphazoline—Nervousness—Lisinopril—systemic scleroderma	0.00829	0.00829	CcSEcCtD
Naphazoline—Hypertension—Mycophenolic acid—systemic scleroderma	0.00818	0.00818	CcSEcCtD
Naphazoline—Headache—Pentoxifylline—systemic scleroderma	0.00813	0.00813	CcSEcCtD
Naphazoline—Vision blurred—Lisinopril—systemic scleroderma	0.00804	0.00804	CcSEcCtD
Naphazoline—Asthenia—Mometasone—systemic scleroderma	0.00803	0.00803	CcSEcCtD
Naphazoline—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00802	0.00802	CcSEcCtD
Naphazoline—Discomfort—Mycophenolic acid—systemic scleroderma	0.00797	0.00797	CcSEcCtD
Naphazoline—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00783	0.00783	CcSEcCtD
Naphazoline—Nausea—Pentoxifylline—systemic scleroderma	0.00771	0.00771	CcSEcCtD
Naphazoline—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00747	0.00747	CcSEcCtD
Naphazoline—Tension—Mycophenolate mofetil—systemic scleroderma	0.00734	0.00734	CcSEcCtD
Naphazoline—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00726	0.00726	CcSEcCtD
Naphazoline—Discomfort—Lisinopril—systemic scleroderma	0.00718	0.00718	CcSEcCtD
Naphazoline—Asthenia—Captopril—systemic scleroderma	0.00705	0.00705	CcSEcCtD
Naphazoline—Headache—Mometasone—systemic scleroderma	0.00701	0.00701	CcSEcCtD
Naphazoline—Somnolence—Mycophenolic acid—systemic scleroderma	0.00687	0.00687	CcSEcCtD
Naphazoline—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00673	0.00673	CcSEcCtD
Naphazoline—Nausea—Mometasone—systemic scleroderma	0.00665	0.00665	CcSEcCtD
Naphazoline—Hyperglycaemia—Prednisone—systemic scleroderma	0.00656	0.00656	CcSEcCtD
Naphazoline—Dizziness—Captopril—systemic scleroderma	0.0065	0.0065	CcSEcCtD
Naphazoline—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00645	0.00645	CcSEcCtD
Naphazoline—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00629	0.00629	CcSEcCtD
Naphazoline—Somnolence—Lisinopril—systemic scleroderma	0.00619	0.00619	CcSEcCtD
Naphazoline—Headache—Captopril—systemic scleroderma	0.00616	0.00616	CcSEcCtD
Naphazoline—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.0059	0.0059	CcSEcCtD
Naphazoline—Nausea—Captopril—systemic scleroderma	0.00584	0.00584	CcSEcCtD
Naphazoline—Asthenia—Leflunomide—systemic scleroderma	0.00581	0.00581	CcSEcCtD
Naphazoline—Dizziness—Azathioprine—systemic scleroderma	0.00567	0.00567	CcSEcCtD
Naphazoline—Asthenia—Mycophenolic acid—systemic scleroderma	0.00555	0.00555	CcSEcCtD
Naphazoline—Eye disorder—Prednisone—systemic scleroderma	0.00544	0.00544	CcSEcCtD
Naphazoline—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00542	0.00542	CcSEcCtD
Naphazoline—Drowsiness—Methotrexate—systemic scleroderma	0.00542	0.00542	CcSEcCtD
Naphazoline—Headache—Azathioprine—systemic scleroderma	0.00538	0.00538	CcSEcCtD
Naphazoline—Dizziness—Leflunomide—systemic scleroderma	0.00536	0.00536	CcSEcCtD
Naphazoline—Sweating—Methotrexate—systemic scleroderma	0.00519	0.00519	CcSEcCtD
Naphazoline—Dizziness—Mycophenolic acid—systemic scleroderma	0.00511	0.00511	CcSEcCtD
Naphazoline—Nausea—Azathioprine—systemic scleroderma	0.0051	0.0051	CcSEcCtD
Naphazoline—Headache—Leflunomide—systemic scleroderma	0.00508	0.00508	CcSEcCtD
Naphazoline—Erythema—Prednisone—systemic scleroderma	0.00507	0.00507	CcSEcCtD
Naphazoline—Asthenia—Lisinopril—systemic scleroderma	0.005	0.005	CcSEcCtD
Naphazoline—Headache—Mycophenolic acid—systemic scleroderma	0.00484	0.00484	CcSEcCtD
Naphazoline—Nausea—Leflunomide—systemic scleroderma	0.00481	0.00481	CcSEcCtD
Naphazoline—Vision blurred—Prednisone—systemic scleroderma	0.00478	0.00478	CcSEcCtD
Naphazoline—Dizziness—Lisinopril—systemic scleroderma	0.0046	0.0046	CcSEcCtD
Naphazoline—Nausea—Mycophenolic acid—systemic scleroderma	0.00459	0.00459	CcSEcCtD
Naphazoline—Eye disorder—Methotrexate—systemic scleroderma	0.00455	0.00455	CcSEcCtD
Naphazoline—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00438	0.00438	CcSEcCtD
Naphazoline—Hypertension—Prednisone—systemic scleroderma	0.00437	0.00437	CcSEcCtD
Naphazoline—Headache—Lisinopril—systemic scleroderma	0.00436	0.00436	CcSEcCtD
Naphazoline—Discomfort—Prednisone—systemic scleroderma	0.00426	0.00426	CcSEcCtD
Naphazoline—Erythema—Methotrexate—systemic scleroderma	0.00423	0.00423	CcSEcCtD
Naphazoline—Nausea—Lisinopril—systemic scleroderma	0.00414	0.00414	CcSEcCtD
Naphazoline—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00403	0.00403	CcSEcCtD
Naphazoline—Hyperhidrosis—Prednisone—systemic scleroderma	0.004	0.004	CcSEcCtD
Naphazoline—Vision blurred—Methotrexate—systemic scleroderma	0.00399	0.00399	CcSEcCtD
Naphazoline—Headache—Mycophenolate mofetil—systemic scleroderma	0.00382	0.00382	CcSEcCtD
Naphazoline—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00362	0.00362	CcSEcCtD
Naphazoline—Discomfort—Methotrexate—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Naphazoline—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00334	0.00334	CcSEcCtD
Naphazoline—Somnolence—Methotrexate—systemic scleroderma	0.00307	0.00307	CcSEcCtD
Naphazoline—Asthenia—Prednisone—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Naphazoline—Dizziness—Prednisone—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Naphazoline—Headache—Prednisone—systemic scleroderma	0.00259	0.00259	CcSEcCtD
Naphazoline—Asthenia—Methotrexate—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Naphazoline—Nausea—Prednisone—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Naphazoline—Dizziness—Methotrexate—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Naphazoline—Headache—Methotrexate—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Naphazoline—Nausea—Methotrexate—systemic scleroderma	0.00205	0.00205	CcSEcCtD
